The goal of this study was to compare the adult height outcomes of 201 hypopituitary children treated at CHOB with standardized doses of either pGH (n=106, 0.3u/kg/week = 0.15 mg/kg/wk rGH approximately, three times weekly (TIW), IM or SC) or rGH (n=95, 0.3 mg/kg/wk TIW or daily SC). During the pGH era (1964-1985) GH treatment was given 9 -12 months each year in contrast to the rGH era when treatment was continuous. All patients exhibited a peak GH response to two provocative tests of <10 ng/ml(polyclonal radioimmunoassay).

Conclusions: GH deficient children treated with pGH were significantly younger and shorter at start of GH treatment compared to those given rGH. Age bias for rGH group resulted from selection of patients who reached final height. Midparental Hts were similar for the two groups. Final Ht and Final Ht SDS (standard deviation score) for both sexes were significantly greater after rGH vs. pGH treatment. Ht gain SDS after pGH was 1.3 and after rGH was 1.4 Duration of GH treatment was longer for pGH (5 yrs) compared to rGH (3.8 yrs). Additional improvements in final heights for the rGH group will likely occur when younger GH deficient children treated for longer durations reach their adult hts. Results (mean)::Table Genentech Foundation for Growth and Development

Table 1
Full size table

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD